Large clinical trial will test combination monoclonal antibody therapy for mild/moderate COVID-19
05/01/2021
The Phase 2/3 clinical trial will evaluate experimental antibodies BRII-196 and BRII-198.
The Phase 2/3 clinical trial will evaluate experimental antibodies BRII-196 and BRII-198.